Lucid diagnostics inc.LUCD.US Overview

US StockHealthcare

(No presentation for LUCD)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

LUCD Overall Performance

LUCD AI Analysis & Strategy

LUCD Recent Performance

3.88%

Lucid diagnostics inc.

0.81%

Avg of Sector

-1.14%

S&P500

LUCD PowerScanner

LUCD Key Information

LUCD Valuation Metrics

LUCD Earnings Table

LUCD Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.